Temozolomide in malignant gliomas: Current use and future targets

J. Lee Villano; Tara E. Seery; Linda R. Bressler

doi:10.1007/s00280-009-1050-5

Temozolomide in malignant gliomas: Current use and future targets

J. Lee Villano
, Tara E. Seery
, Linda R. Bressler

Producción científica: Short survey › revisión exhaustiva

171 Citas (Scopus)

Resumen

Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

Idioma original	English
Páginas (desde-hasta)	647-655
Número de páginas	9
Publicación	Cancer Chemotherapy and Pharmacology
Volumen	64
N.º	4
DOI	https://doi.org/10.1007/s00280-009-1050-5
Estado	Published - sept 2009

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Acceder al documento

10.1007/s00280-009-1050-5

Otros archivos y enlaces

Citar esto

@article{d9cd8724337c470687325771656bf092,

title = "Temozolomide in malignant gliomas: Current use and future targets",

abstract = "Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.",

keywords = "Alkylating chemotherapy, Brain tumor, Glioblastoma, Malignant glioma, Temozolomide, Tumor resistance",

author = "Villano, \{J. Lee\} and Seery, \{Tara E.\} and Bressler, \{Linda R.\}",

year = "2009",

month = sep,

doi = "10.1007/s00280-009-1050-5",

language = "English",

volume = "64",

pages = "647--655",

number = "4",

}

TY - JOUR

T1 - Temozolomide in malignant gliomas

T2 - Current use and future targets

AU - Villano, J. Lee

AU - Seery, Tara E.

AU - Bressler, Linda R.

PY - 2009/9

Y1 - 2009/9

N2 - Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

AB - Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

KW - Alkylating chemotherapy

KW - Brain tumor

KW - Glioblastoma

KW - Malignant glioma

KW - Temozolomide

KW - Tumor resistance

UR - https://www.scopus.com/pages/publications/68149157509

UR - https://www.scopus.com/pages/publications/68149157509#tab=citedBy

U2 - 10.1007/s00280-009-1050-5

DO - 10.1007/s00280-009-1050-5

M3 - Short survey

C2 - 19543728

AN - SCOPUS:68149157509

SN - 0344-5704

VL - 64

SP - 647

EP - 655

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 4

ER -

Temozolomide in malignant gliomas: Current use and future targets

Resumen

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto